Supernus Pharmaceuticals(SUPN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SUPN Supernus Pharmaceuticals

休市中 07-02 16:00:00 EDT

48.05

+0.64

+1.35%

盘后48.05

+0.000.00%

19:48 EDT

最高48.11	最低46.97	成交量96.90万
今开47.49	昨收47.41	日振幅2.40%
总市值27.89亿	流通市值23.50亿	总股本5,804万
成交额4,611万	换手率1.98%	流通股本4,890万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SUPN","market":"US","secType":"STK","nameCN":"Supernus Pharmaceuticals","latestPrice":48.05,"timestamp":1783022400000,"preClose":47.41,"halted":0,"volume":969033,"hourTrading":{"tag":"盘后","latestPrice":48.05,"preClose":48.05,"latestTime":"19:48 EDT","volume":18385,"amount":883399.31,"timestamp":1783036104579,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01349926175912256,"floatShares":48898547,"shares":58039721,"eps":-0.509975,"marketStatus":"休市中","change":0.64,"latestTime":"07-02 16:00:00 EDT","open":47.49,"high":48.11,"low":46.97,"amount":46106687.0433,"amplitude":0.024046,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.509975,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1335844800000,"exchange":"NASDAQ","adjPreClose":47.41,"preHourTrading":{"tag":"盘前","latestPrice":47.41,"preClose":47.41,"latestTime":"09:25 EDT","volume":24,"amount":1137.84,"timestamp":1782998700008,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":48.05,"preClose":48.05,"latestTime":"19:48 EDT","volume":18385,"amount":883399.31,"timestamp":1783036104579,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6863509767794935,"impliedVol":0.2969,"impliedVolPercentile":0.3625},"requestUrl":"/m/hq/s/SUPN","defaultTab":"news","newsList":[{"id":"1173614980","title":"Supernus Pharmaceuticals达成里程碑一，将根据CVR协议向Equiniti Trust支付每股0.50美元，总额达3340万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173614980","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173614980?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:53","pubTimestamp":1779310403,"startTime":"0","endTime":"0","summary":"根据一项或有价值权协议，Supernus Pharmaceuticals Inc在达成首个里程碑后，将向Equiniti Trust Company支付每股0.50美元的款项。这笔付款总额约为3340万美元，标志着该公司在履行协议义务方面取得了重要进展。该笔资金将由Equiniti Trust Company作为托管代理进行管理并分配给符合条件的CVR持有人。支付流程的启动，反映了Supernus Pharmaceuticals在相关项目上取得了合约约定的阶段性成果。公司此举履行了其财务承诺，并将资金部署至预先约定的渠道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183842053","title":"Supernus Pharmaceuticals Inc协议包含五年竞业禁止与禁止招揽条款 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1183842053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183842053?lang=zh_cn&edition=full","pubTime":"2026-04-08 05:27","pubTimestamp":1775597232,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件披露，Supernus Pharmaceuticals Inc（SUPN）已达成一项重要协议。该协议的关键条款之一，是包含了一项为期五年的竞业禁止与禁止招揽承诺。\n此举旨在保护公司的商业利益和核心团队稳定。此类条款通常用于限制关键人员在一定期限内加入竞争对手或招揽公司客户及员工。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105297423","title":"Supernus Pharmaceuticals收购价包含2B期研究及最高达3.5亿美元的里程碑付款——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1105297423","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105297423?lang=zh_cn&edition=full","pubTime":"2026-04-08 05:27","pubTimestamp":1775597232,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，Supernus Pharmaceuticals公司的收购价格构成中，不仅涵盖了正在进行中的2B期临床研究，还包含了未来可能支付的里程碑款项，其总额最高可达3.5亿美元。\n这一安排凸显了该笔交易对相关资产未来潜力的高度认可。里程碑付款通常与研发进程中的关键节点或未来的商业化成果挂钩，此次高达3.5亿美元的潜在支付额度，无疑为市场提供了关于该资产前景的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120741690","title":"Supernus制药公司于2026年4月1日与Navitor达成资产购买协议 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1120741690","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120741690?lang=zh_cn&edition=full","pubTime":"2026-04-08 05:27","pubTimestamp":1775597231,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，Supernus制药公司已于2026年4月1日与Navitor公司正式签署了一项资产购买协议。此举标志着两家公司在资产交易方面取得了关键性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173253479","title":"Supernus制药公司计划收购NV-5138及SPN-820相关资产——知识产权与库存均包含在内","url":"https://stock-news.laohu8.com/highlight/detail?id=1173253479","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173253479?lang=zh_cn&edition=full","pubTime":"2026-04-08 05:27","pubTimestamp":1775597230,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件披露，Supernus制药公司已达成协议，将收购与候选药物NV-5138（亦称SPN-820）相关的资产组合。此次交易标的不仅涵盖了该药物的核心知识产权，还包括其现有库存。这一举措标志着Supernus制药在其产品管线拓展战略上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139630013","title":"财报前瞻｜Supernus Pharmaceuticals本季度营收预计增25.33%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1139630013","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139630013?lang=zh_cn&edition=full","pubTime":"2026-02-17 11:50","pubTimestamp":1771300212,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals将于2026年02月24日发布新一季财报，市场关注营收加速与盈利修复节奏。一致预期显示，本季度Supernus Pharmaceuticals营收预计为1.95亿美元，同比增长25.33%；调整后每股收益预计为0.36美元，同比下降13.25%；息税前利润预计为2,624.90万美元，同比下降15.48%；毛利率与净利率暂无明确一致预期或公司量化指引可供引用。上季度Supernus Pharmaceuticals实现营收1.92亿美元，同比增长9.34%；毛利率为74.84%；归属于母公司股东的净亏损4,511.70万美元，净利率为-23.49%；调整后每股收益为1.01美元，同比下降13.68%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Supernus Pharmaceuticals本季度营收预计增25.33%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516552739","title":"Supernus Pharmaceuticals, Inc.2024财年实现净利润73.87百万美元，同比增加5496.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516552739?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844866,"startTime":"0","endTime":"0","summary":"3月2日，Supernus Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为73.87百万美元，同比增加5496.21%；其中营业收入为6.62亿美元，同比增加8.88%，每股基本收益为1.34美元。机构评级：截至2025年3月2日，当前有5家机构对Supernus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为38.80美元，其中最低目标价为36.00美元，最高目标价为44.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000137abe2c5c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000137abe2c5c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514562568","title":"Supernus Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.49%报31.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514562568","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514562568?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:40","pubTimestamp":1740580827,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时40分，Supernus Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.49%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.14%。其相关个股中，Sunshine Biopharma Inc C/Wts 、Scilex Holding Company C/Wts 10/11/2027 、Lantheus Holdings, Inc.涨幅较大，苏轩堂、Petros Pharmaceuticals, Inc.、Quantum Biopharma Ltd.较为活跃，换手率分别为8.74%、8.48%、4.06%，振幅较大的相关个股有Sunshine Biopharma Inc C/Wts 、Petros Pharmaceuticals, Inc.、Optinose, Inc.，振幅分别为35.75%、13.37%、12.52%。Supernus Pharmaceuticals, Inc.公司简介：Supernus Pharmaceuticals Inc 是一家专业制药公司，致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262240279893ac8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262240279893ac8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188069609","title":"Supernus Pharmaceuticals第四季度每股收益$0.27低于预期$0.52，销售额$1.7416亿超预期$1.5525亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1188069609","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188069609?lang=zh_cn&edition=full","pubTime":"2025-02-26 05:12","pubTimestamp":1740517973,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals报告称季度每股收益为$0.27，与分析师普遍预期的$0.52相比低了48.08%。与去年同期的$0.39每股收益相比，下降了30.77%。公司报告季度销售额为$1.7416亿，超出分析师普遍预期的$1.5525亿，超出比例为12.18%。以上内容来自Benzinga Earnings专栏，原文如下：$Supernus Pharmaceuticals$  reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.52 by 48.08 percent. This is a 30.77 percent decrease over earnings of $0.39 per share from the same period last year.  The company reported quarterly sales of $174.16 million which beat the analyst co","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Supernus Pharmaceuticals第四季度每股收益$0.27低于预期$0.52，销售额$1.7416亿超预期$1.5525亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512483965","title":"Supernus Pharmaceuticals, Inc.股价重挫16.98% 市值跌3.09亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512483965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512483965?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:31","pubTimestamp":1739975488,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时31分，Supernus Pharmaceuticals, Inc.股票出现波动，股价快速下跌16.98%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.15%。其相关个股中，Medicus Pharma Ltd.、和黄医药、Cardiol Therapeutics Inc.涨幅较大，Petros Pharmaceuticals, Inc.、Painreform Ltd.、大自然药业较为活跃，换手率分别为16.93%、14.69%、5.82%，振幅较大的相关个股有大自然药业、Rockwell Medical, Inc.、Petros Pharmaceuticals, Inc.，振幅分别为3.29%、3.16%、2.93%。Supernus Pharmaceuticals, Inc.公司简介：Supernus Pharmaceuticals Inc 是一家专业制药公司，致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223128a24bf948&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223128a24bf948&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175193020","title":"美股夜盘｜超微电脑续涨7%，该股月内股价接近翻倍；Arista Networks绩后跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175193020","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175193020?lang=zh_cn&edition=full","pubTime":"2025-02-19 09:06","pubTimestamp":1739927178,"startTime":"0","endTime":"0","summary":"2月19日，美股夜盘时段，超微电脑续涨7%，该股隔夜暴涨逾16%，月内股价接近翻倍。Arista Networks跌超5%，此前发布Q4最新业绩，第四季度业绩超预期，本季度营收指引强劲。制药公司Supernus暴跌逾10%，抑郁症治疗中期试验失败。西方石油跌近1%，Q4营收同比下滑，净利同比由盈转亏。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMCI","SUPN","BK4588","LU0053671581.USD","LU1861215975.USD","LU1861220033.SGD","ANET","BK4585","BK4170"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2508457218","title":"Supernus Pharmaceuticals, Inc.盘中异动 快速拉升5.35%报39.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508457218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508457218?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:32","pubTimestamp":1738679563,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时32分，Supernus Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.35%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中，整体跌幅为0.39%。其相关个股中，Quantum Biopharma Ltd.、坎伯兰药业、Talphera, Inc.涨幅较大，Quantum Biopharma Ltd.、坎伯兰药业、大自然药业较为活跃，换手率分别为1086.36%、57.17%、6.03%，振幅较大的相关个股有Quantum Biopharma Ltd.、Talphera, Inc.、Redhill Biopharma Ltd，振幅分别为24.20%、7.01%、5.95%。Supernus Pharmaceuticals, Inc.公司简介：Supernus Pharmaceuticals Inc 是一家专业制药公司，致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223243a2392912&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223243a2392912&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508147595","title":"Supernus Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.00%报36.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508147595","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508147595?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:46","pubTimestamp":1738597579,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时46分，Supernus Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.00%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中，整体跌幅为0.52%。其相关个股中，Cbdmd, Inc.、艾伯维公司、Incannex Healthcare Inc.涨幅较大，Inmed Pharmaceuticals Inc.、Painreform Ltd.、Cbdmd, Inc.较为活跃，换手率分别为35.37%、7.09%、4.83%，振幅较大的相关个股有Procaps Group S.A. C/Wts 29/09/2026 、Procaps Group, S.A.、Alvotech C/Wts ，振幅分别为46.33%、19.44%、15.25%。Supernus Pharmaceuticals, Inc.公司简介：Supernus Pharmaceuticals Inc 是一家专业制药公司，致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020323462098797b23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020323462098797b23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483334442","title":"Supernus Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.00%报35.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483334442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483334442?lang=zh_cn&edition=full","pubTime":"2024-11-15 04:17","pubTimestamp":1731615445,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日04时17分，Supernus Pharmaceuticals, Inc.股票出现波动，股价急速下挫5.00%。截至发稿，该股报35.88美元/股，成交量22.8959万股，换手率0.41%，振幅6.45%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中，整体跌幅为1.35%。Supernus Pharmaceuticals, Inc.公司简介：Supernus Pharmaceuticals Inc 是一家专业制药公司，致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115041725abc20745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115041725abc20745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2482267310","title":"Supernus Pharmaceuticals, Inc.2024财年第三财季实现净利润38.50百万美元，同比增加340.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482267310","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482267310?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:00","pubTimestamp":1731254419,"startTime":"0","endTime":"0","summary":"11月11日，Supernus Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为38.50百万美元，同比增加340.93%；其中营业收入为1.76亿美元，同比增加14.29%，每股基本收益为0.70美元。机构评级：截至2024年11月11日，当前有4家机构对Supernus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为39.25美元，其中最低目标价为36.00美元，最高目标价为43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000029abb361fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000029abb361fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481500384","title":"Supernus Pharmaceuticals, Inc.盘中异动 股价大涨9.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481500384","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481500384?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:32","pubTimestamp":1730817124,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日22时32分，Supernus Pharmaceuticals, Inc.股票出现波动，股价急速上涨9.02%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中，整体跌幅为0.34%。其相关个股中，Supernus Pharmaceuticals, Inc.、Evotec Se、阿尔凯默斯涨幅较大，Biofrontera Inc.、Canopy Growth Corporation、Evoke Pharma, Inc.较为活跃，换手率分别为2.02%、0.53%、0.39%，振幅较大的相关个股有Aquestive Therapeutics, Inc.、Painreform Ltd.、Supernus Pharmaceuticals, Inc.，振幅分别为7.77%、6.72%、3.89%。Supernus Pharmaceuticals, Inc.公司简介：Supernus Pharmaceuticals Inc 是一家专业制药公司，致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110522320495bdd1f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110522320495bdd1f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192290637","title":"异动解读 | Supernus Pharmaceuticals业绩亮眼 盘前大涨9.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192290637","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192290637?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:30","pubTimestamp":1730817036,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals公司在2024年第三季度表现出色,财报数据亮眼,引发了股价在盘前大涨9.37%的行情。财报显示,Supernus Pharmaceuticals第三季度实现营收1.76亿美元,同比增长14.2%,超过了分析师预期。此次财报超预期反映了Supernus Pharmaceuticals产品的强劲市场需求和较高的盈利能力。在目前医药行业竞争激烈的环境下,Supernus Pharmaceuticals显现出了较强的商业运营能力。市场普遍预计,公司未来仍将保持良好的发展势头。目前机构分析师给予该股\"买入\"评级,认为公司具有较高的长期成长潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171699565","title":"异动解读 | Supernus Pharmaceuticals公司财报佳绩 盘后大涨6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171699565","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171699565?lang=zh_cn&edition=full","pubTime":"2024-11-05 16:02","pubTimestamp":1730793756,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals公司最新公布的2024年第三季度财报数据亮眼,业绩超出市场预期,引发股价在盘后大幅上涨。\n\n财报显示,公司第三季度每股收益为69美分,高于分析师平均预期的44美分。营收同比增长14.2%至1.76亿美元,也超过了分析师预期的1.57亿美元。公司本季度净收入达到3850万美元。\n\n优异的财报数据令投资者对Supernus Pharmaceuticals的长期盈利前景充满信心。目前分析师普遍给予该股\"买入\"评级,认为公司具有较强的盈利能力,看好其在医药行业的发展前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SUPN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.supernus.com","stockEarnings":[{"period":"1week","weight":0.0737},{"period":"1month","weight":0.0903},{"period":"3month","weight":-0.0481},{"period":"6month","weight":-0.0287},{"period":"1year","weight":0.4983},{"period":"ytd","weight":-0.0332}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Supernus Pharmaceuticals, Inc.于2005年3月30日在美国特拉华州注册成立，并于2005年12月22日开始运营。该公司是一家生物制药公司，专注于开发和商业化用于治疗中枢神经系统疾病的产品。该公司多样化的神经科学产品组合包括已获批准的治疗注意力缺陷多动障碍、接受左旋多巴治疗的帕金森病患者的运动障碍、PD中的低活动性、癫痫、偏头痛、颈椎肌张力障碍和慢性唾液流。该公司正在开发范围广泛的新型CNS候选产品，包括治疗癫痫、抑郁症和其他CNS疾病的新的潜在疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.054207},{"month":2,"riseRate":0.5,"avgChangeRate":-0.006771},{"month":3,"riseRate":0.5,"avgChangeRate":0.035893},{"month":4,"riseRate":0.571429,"avgChangeRate":0.019854},{"month":5,"riseRate":0.5,"avgChangeRate":0.042721},{"month":6,"riseRate":0.666667,"avgChangeRate":0.090772},{"month":7,"riseRate":0.666667,"avgChangeRate":0.033822},{"month":8,"riseRate":0.571429,"avgChangeRate":0.016165},{"month":9,"riseRate":0.357143,"avgChangeRate":-0.022786},{"month":10,"riseRate":0.5,"avgChangeRate":-0.001556},{"month":11,"riseRate":0.571429,"avgChangeRate":-0.006005},{"month":12,"riseRate":0.5,"avgChangeRate":-0.005978}],"exchange":"NASDAQ","name":"Supernus Pharmaceuticals","nameEN":"Supernus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Supernus Pharmaceuticals(SUPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Supernus Pharmaceuticals(SUPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Supernus Pharmaceuticals,SUPN,Supernus Pharmaceuticals股票,Supernus Pharmaceuticals股票老虎,Supernus Pharmaceuticals股票老虎国际,Supernus Pharmaceuticals行情,Supernus Pharmaceuticals股票行情,Supernus Pharmaceuticals股价,Supernus Pharmaceuticals股市,Supernus Pharmaceuticals股票价格,Supernus Pharmaceuticals股票交易,Supernus Pharmaceuticals股票购买,Supernus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Supernus Pharmaceuticals(SUPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Supernus Pharmaceuticals(SUPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}